CUSIP: 114082100
Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
15,186,440
-
Share change
-
-3,406,432
-
Total reported value
-
$7,859,000
-
Price per share
-
$0.52
-
Number of holders
-
34
-
Value change
-
-$2,827,937
-
Number of buys
-
20
-
Number of sells
-
36
Quarterly Holders Quick Answers
What is CUSIP 114082100?
CUSIP 114082100 identifies BTX - BROOKLYN IMMUNOTHERAPEUTICS - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2022
-
Previous quarter:
Q1 2022
Recent filing periods for CUSIP 114082100:
Institutional Holders of BROOKLYN IMMUNOTHERAPEUTICS - COM (BTX) as of Q2 2022
As of 30 Jun 2022,
BROOKLYN IMMUNOTHERAPEUTICS - COM (BTX) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,186,440 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, Cypress Point Wealth Management, LLC, Naviter Wealth, LLC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., INVERNESS COUNSEL LLC /NY/, VANGUARD GROUP INC, JPMORGAN CHASE & CO, MILLENNIUM MANAGEMENT LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.